RT Journal Article SR Electronic T1 Plasma Amino Acids Metabolomics’ Profile Important for Glucose Management in Jordanian people with Type 2 Diabetes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.24.21252345 DO 10.1101/2021.02.24.21252345 A1 Abdelrahim Alqudah A1 Mohammed Wedyan A1 Esam Qnais A1 Hassan Jawarneh A1 Lana McClements YR 2021 UL http://medrxiv.org/content/early/2021/02/26/2021.02.24.21252345.abstract AB Background The disturbances in plasma free amino acid metabolome in diabetes mellitus was studied before but not in Jordanian population. This study aimed to assess the association between type 2 diabetes (T2D) and amino acid metabolome in a representative group of people from Jordan.Methods Blood samples from 124 people with T2D and 67 age-, gender- and BMI-matched healthy controls were collected and assayed for glucose and HbA1c. Twenty one amino acids belonging to different categories (essential, non-essential, semi-essential, and metabolic indicators) were evaluated in both groups using amino acids analyser.Results Plasma free amino acids concentrations of total amino acids, total essential amino acids, total non-essential amino acids, and total semi-essential amino acids were not different in T2D compared to healthy controls. However, plasma concentrations of four essential amino acids (Leucine, Lysine, Phenylalanine, Tryptophan) were increased in the presence of T2D (Leucine, p<0.01, Lysine, p<0.001, Phenylalanine, p<0.01, Tryptophan, p<0.05). Conversely, amongst the non-essential amino acids, Alanine and Serine were reduced in type 2 diabetes (Alanine, p<0.01, Serine, p<0.001), whereas, Aspartate and Glutamate were increased in T2D compared to healthy control plasma (Aspartate, p<0.001, Glutamate, p<0.01). A semi-essential amino acid, Cystine, was also increased in T2D compared to healthy controls (p<0.01). Citrulline, a metabolic indicator amino acid, demonstrated lower plasma concentration in T2Dcompared to healthy controls (p<0.01).Conclusion Several amino acids from different categories are dysregulated in T2D, which could be used as a therapeutic target to improve T2D management and its complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported from the Deanship of Scientific Research at the Hashemite University, Jordan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Institutional Review Board (IRB number 6/7/2017/2018) at the Hashemite University, Zarqa, Jordan, and all procedures followed were in accordance with the 1964 Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.